This study is a collaboration between the University of Arizona and the University of Florida. The study will help researchers to learn more about the usefulness of a brain health intervention known as low-level light therapy or near-infrared photobiomodulation.
The SHINE study is evaluating the study drug, CT1812, in adults ages 50 to 85 who have been diagnosed with mild to moderate Alzheimer’s disease.
The purpose of this research study is to learn about the safety of CT1812 and how well you or your loved one tolerate(s) a once-a-day dose of CT1812. The study will also test how well CT1812 will treat mild to moderate AD.
Up to 144 participants will be enrolled in the SHINE study.
The Trial-Ready Cohort-Down Syndrome (TRC-DS) is a volunteer cohort of individuals with Down syndrome (DS) to advance Alzheimer’s disease (AD) clinical trial involvement in the future.
The WeCareAdvisor is an innovative tool developed by researchers at Drexel University and University of California, Davis to help family caregivers manage common behavioral and psychological symptoms of dementia (like anger, irritability, asking repeated questions, pacing, refusing needed help, and many others). The WeCareAdvisor works on any internet-accessible device, including desktop and laptop computers, tablets, and smartphone and is simple to use.